more about global ibogaine conference

press release:

Between March 14-16th, 2016 in Tepoztlan, Mexico, the 2016 Global Ibogaine Conference will convene experts from around the world to discuss ibogaine therapy, the climate of global drug policy, and the sustainability and traditional uses of Tabernanthe iboga.

Since the 1980s ibogaine, the primary psychoactive extract of T. iboga, has increasingly been used experimentally in the detoxification from opiates and as a treatment for substance use disorders. Early clinical trials confirmed some very promising initial reports, but were later suspended because of funding and litigation. Ibogaine’s use has continued to grow, from the early peer-to-peer drug user networks, to today when ibogaine is administered under compassionate access or experimental legal frameworks in some progressive hospitals, medical centers, retreats, and private therapeutic practices around the world. The landscape of ibogaine research and practice has changed dramatically. Today clinical investigations are being re-initiated looking not only at its use in addiction treatment, but also other conditions.

The event is a partnership between The Global Ibogaine Therapy Alliance (GITA), the International Center for Ethnobotanical Education, Research & Service (ICEERS), and Espolea (Mexico City). It is the 5th international conference hosted by GITA, and the first major public conference in the series. It features influential speakers from across the fields of psychology, harm reduction, and drug policy reform, and ibogaine research, including Claudio Naranjo, Stanton Peele, Kenneth Alper, Jeffrey Kamlet, Andrew Tatarski, and many others.

The conference pre-session from March 12-13th, 2016 will be the first ever Advanced Cardiac Life Support (ACLS) Certification for Ibogaine Therapists. course, available through GITA, goes beyond the standards emergency protocols certified by the American Heart Association to discuss practical concerns for monitoring patients in a clinical setting. It will also include important changes to ACLS interventions and appropriate medications to avoid negative interaction, in order to prevent emergency situations during ibogaine administration.

Registration for the event as well as the pre- and post-conference sessions, will open on August 1st, 2015. For more information about the conference, including confirmed speakers, program outline, and to sign up for email updates, please visit: http://www.ibogaineconference.org